Streetbeat News

Products Services

VIGL

Vigil Neuroscience Inc. (NASDAQ:VIGL) released interim data from its Phase 1 clinical trial of VG-3927, a novel small molecule TREM2 agonist for treating Alzheimer's disease. The data showed positive safety, tolerability, and pharmacokinetic profiles, supporting further development. The stock rose 6.52% following the news.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 7:12 pm

JBLU

JetBlue is expanding its services in New England by adding 20% more seats this winter. The airline is also launching new routes, including Manchester and Buffalo to West Palm Beach, with fares starting at $49.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:08 pm

GILD

Campaigners are urging Gilead Sciences Inc. to significantly reduce the price of its HIV prevention drug, lenacapavir, which is currently priced at $42,250 annually but could be produced for just $40. The drug, sold as Sunlenca, has shown 100% efficacy in preventing HIV in cisgender women in a Phase 3 trial. Gilead is awaiting further clinical trial data and regulatory approvals before pricing lenacapavir for prevention.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 7:04 pm

BITW

BLK

ETHE

Spot Ethereum ETFs had a strong first trading day, with significant inflows and trading volumes. Analysts are optimistic about Ethereum's price breaking its current consolidation and reaching new all-time highs. Major demand was noted for BlackRock's and Bitwise's products, while Grayscale saw outflows.

Portfolio Pulse from Khyathi Dalal

July 24, 2024 | 7:02 pm

AAPL

GOOG

GOOGL

Apple has launched a beta version of Apple Maps on the web, expanding its mapping service beyond iOS devices. This move could enhance Apple's ecosystem and compete more directly with Google Maps.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 7:02 pm

NVO

The UK's NHS has prescribed Novo Nordisk's weight-loss drug Wegovy far less than expected due to a shortage of weight management clinics. Despite high demand and regulatory approval for reducing heart risks, the drug's international supply is limited. The NHS has prioritized supplies of Ozempic, another Novo Nordisk drug for type-2 diabetes, over Wegovy. The shortfall is also due to a lack of specialist NHS weight-loss services.

Portfolio Pulse from Vandana Singh

July 24, 2024 | 6:58 pm

META

NVDA

Meta Platforms, Inc. (NASDAQ:META) shares are trading lower as the broader market pulls back, influenced by disappointing earnings from Tesla and Alphabet. Meta announced the launch of its latest version of 'Llama' AI software, which is integrated into its suite of applications. NVIDIA Corp (NASDAQ:NVDA) also announced new AI services in connection with Meta's release.

Portfolio Pulse from Erica Kollmann

July 24, 2024 | 6:55 pm

CMCSA

DKNG

Scottie Scheffler, a dominant golfer in the 2024 PGA Tour season, is set to compete in the 2024 Summer Olympics. Alongside him, Xander Schauffele, Wyndham Clark, and Collin Morikawa will represent Team USA. Scheffler is the betting favorite, with odds provided by DraftKings Inc (NASDAQ:DKNG). The event will be streamed by Comcast Corp (NASDAQ:CMCSA) on Peacock.

Portfolio Pulse from Chris Katje

July 24, 2024 | 6:50 pm

AAPL

Apple Inc (NASDAQ:AAPL) is set to release its Q3 2024 earnings report, with JPMorgan analyst Samik Chatterjee predicting a strong performance driven by AI advancements. Chatterjee has raised the price target to $265 by December 2025, citing expected revenue and earnings beats, particularly from iPhone sales. The AI cycle is seen as a key growth driver, potentially boosting margins, volumes, and extending the replacement cycle.

Portfolio Pulse from Surbhi Jain

July 24, 2024 | 6:47 pm

AZTR

LW

NUWE

PIRS

PRG

SGMO

T

U.S. stocks traded lower with the S&P 500 falling around 100 points. AT&T shares rose 5% after Q2 earnings, despite missing revenue estimates. Pieris Pharmaceuticals surged 78% on a merger agreement, while Sangamo Therapeutics rose 47% after a successful trial. PROG Holdings gained 21% on strong earnings. Azitra, Nuwellis, and Lamb Weston saw significant declines due to various financial issues.

Portfolio Pulse from Avi Kapoor

July 24, 2024 | 6:37 pm